ETFs
B
BMRN
Biomarin Pharmaceutical Inc
59.33
+0.46+0.78%After Hours: 59.50 +0.17 +0.29%19:34 07/24 EDT
OPEN/PREV CLOSE59.24/58.87
TODAY RANGE58.61-59.35
VOL1.94M
MARKET CAP11.47B
52 WEEK RANGE49.26-66.28
AVG VOL (3M)2.07M
% TURNOVER1.00%
TURNOVER--
P/E (TTM)43.29
% RANGE1.26%
EPS(TTM)1.370
P/E(FORWARD)16.48
P/B1.846
BVPS32.14
DIVIDEND--
P/S3.542
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP11.43B
SHARES OUTSTANDING193.28M
NEXT EARNINGS08/03-08/07
FREE FLOAT192.60M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·1d ago
BioMarin Pharmaceutical (BMRN) On FDA Acceptance For VOXZOGO And The Valuation Case
TipRanks·3d ago
BioMarin Pharmaceutical (BMRN) Gets a Buy from Barclays
Seeking Alpha·3d ago
BioMarin: Commercial Infrastructure Is The Hidden Growth Asset
Simply Wall St·07/17 21:29
How FDA Review of VOXZOGO Full-Approval Data at BioMarin (BMRN) Has Changed Its Investment Story
Dow Jones·07/16 20:29
BioMarin Pharmaceutical Is Maintained at Buy by Citigroup
Dow Jones·07/16 20:29
BioMarin Pharmaceutical Price Target Raised to $76.00/Share From $75.00 by Citigroup
Benzinga·07/16 20:19
Citigroup Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $76
TipRanks·07/16 10:35
BioMarin price target raised to $76 from $75 at Citi
Simply Wall St·07/16 10:25
BioMarin (BMRN) Wins FDA Review For VOXZOGO Full Approval In Achondroplasia
Seeking Alpha·07/13 16:23
BioMarin sNDA seeking full Voxzogo approval accepted by FDA
NASDAQ·07/13 15:19
BioMarin Seeks Full FDA Approval For VOXZOGO In Achondroplasia
TipRanks·07/13 13:10
BioMarin announces FDA accepts sNDA for full approval of Voxzogo
Same Industry
Name/Symbol
Change%
Price